Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2201 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
/PRNewswire/ -- Chengdu Origen Biotechnology Co., Ltd. ("Chengdu Origen") and Vanotech Ltd. ("Vanotech") announced today the first patient dosed in the...
Source: prnewswire.com